Expression of the Bcl-2 family genes and complexes involved in the mitochondrial transport in prostate cancer cells

International Journal of Oncology

Volumn 45, Issue 4, 2014, Pages 1489-1496

  Asmarinah, ^a   Paradowska Dogan, Agnieszka ^b   Kodariah, Ria ^a   Tanuhardja, Budiana ^a   Waliszewski, Przemyslaw ^b   Mochtar, Chaidir Arif ^c   Budiningsih, Yuli ^a   Weidner, Wolfgang ^b   Hinsch, Elvira ^b  

^a UNIVERSITY OF INDONESIA   (Indonesia)

^b Faculty of Veterinary Medicine   (Germany)

^c CIPTO MANGUNKUSUMO HOSPITAL   (Indonesia)

Author keywords

Bcl 2 family; Prostate cancer; Translocases of the outer mitochondrial membrane expression; Voltage dependent anion channels

Indexed keywords

MULTIPROTEIN COMPLEX; PARAFFIN; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BID; TRANSLOCASE OF OUTER MITOCHONDRIAL MEMBRANE 20; TRANSLOCASE OF OUTER MITOCHONDRIAL MEMBRANE 22; TRANSLOCASE OF OUTER MITOCHONDRIAL MEMBRANE 40; UNCLASSIFIED DRUG; VOLTAGE DEPENDENT ANION CHANNEL 1; VOLTAGE DEPENDENT ANION CHANNEL 2; VOLTAGE DEPENDENT ANION CHANNEL 3; BAX PROTEIN, HUMAN; CARRIER PROTEIN; VOLTAGE DEPENDENT ANION CHANNEL;

ADOLESCENT; ADULT; ARTICLE; CARCINOGENESIS; CELL TRANSPORT; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MITOCHONDRIAL GENE; MITOCHONDRIAL MEMBRANE; MULTIGENE FAMILY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; SECRETORY CELL; SIGNAL TRANSDUCTION; TRANSLATION REGULATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MITOCHONDRION; PATHOLOGY; PROSTATE TUMOR; YOUNG ADULT;

ADOLESCENT; ADULT; BCL-2-ASSOCIATED X PROTEIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MEMBRANE TRANSPORT PROTEINS; MITOCHONDRIA; MITOCHONDRIAL MEMBRANES; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; VOLTAGE-DEPENDENT ANION CHANNELS; YOUNG ADULT;

EID: 84907474116     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2576     Document Type: Article

References (41)

1. Adams JM: Ways of dying: multiple pathways to apoptosis. Genes Dev 17: 2481-2495, 2003.
2. Thompson CB: Apoptosis in the pathogenesis and treatment of disease. Science 267: 1456-1462, 1995.
3. Bidere N, Su HC and Lenardo MJ: Genetic disorders of programmed cell death in the immune system. Annu Rev Immunol 24: 321-352, 2006.
4. Danial NN and Korsmeyer SJ: Cell death: critical control points. Cell 116: 205-219, 2004. (Pubitemid 38167313)
5. Wong RBY: Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res 30: 87, 2011.
6. Ola MS, Nawaz M and Ahsan H: Role of Bcl-2 family proteins and caspases in the regulation of apoptosis. Mol Cell Biochem 351: 41-58, 2011.
7. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, et al : Expression of the protooncogene BCL-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52: 6940-6944, 1992. (Pubitemid 23006303)
8. Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS and Buttyan R: Overexpression of BCL-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 55: 4438-4445, 1995.
9. McConkey DJ, Greene G and Pettaway CA: Apoptosis resistance increase with metastatic potential in cells of the human LNCaP prostate carcinoma line. Cancer Res 56: 5594-5599, 1996. (Pubitemid 26422158)
10. Fuzio P, Ditonno P, Lucarelli G, Battaglia M, Bettocchi C, Senia T and Perlino E: Androgen deprivation therapy affects BCL-2 expression in human prostate cancer. Int J Oncol 39: 1233-1242, 2011.
11. Yoshino T, Shiina H, Urakami, S, Kikuno N, Yoneda T, Shigeno K and Igawa M: Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy. Clin Cancer Res 12: 6116-6124, 2006. (Pubitemid 44703777)
12. Geula S, Ben-hail D and Shoshan-Barmartz V: Structure-based analysis of VDAC1: N-terminus location, translocation, channel gating and association with anti-apoptotic protein. Biochem J 444: 475-485, 2012.
13. Messina A, Reina S, Guarino F and De Pinto V: VDAC isoforms in mammals. Biochim Biophys Act 1818: 1466-1476, 2012.
14. Shimizu S, Matsuoka Y, Shinohara Y, Yoneda Y and Tsujimoto Y: Essential role of voltage-dependent anion channel in various forms of apoptosis in mammalian cells. J Cell Biol 152: 237-250, 2001. (Pubitemid 34285595)
15. Shore GC: Apoptosis: it's Bak to VDAC. EMBO Rep 10: 1311-1313, 2009.
16. Abu-Hamad S, Arbel N, Calo D, Arzoine L, Israelson A, Keinan N, Ben-Romano R, Friedman O and Shoshan-Barmatz V: The VDAC1 N-terminus is essential both for apoptosis and the protective effect of anti-apoptotic proteins. J Cell Sci 122: 1906-1916, 2009.
17. Bellot G, Cartron PF, Er E, Oliver L, Juin P, Armstrong LC, Bornstein P, Mihara K, Manon S and Vallette FM: TOM22, a core component of the mitochondria outer membrane protein translocation pore, is a mitochondrial receptor for the proapoptotic protein Bax. Cell Death Differ 14: 785-794, 2007. (Pubitemid 46444516)
18. Ott M, Norberg E, Zhivotovsky B and Orrenius S: Mitochondrial targeting of tBid/Bax: a role for the TOM complex? Cell Death Differ 16: 1075-1078, 2009.
19. Cassará MC, Menzel VA, Hinsch KD, Wrenzycki C and Hinsch E: Voltage-dependent anion channels 1 and 2 are expressed in porcine oocytes. Biosci Rep 30: 193-200, 2009.
20. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A and Speleman F: Accurate normalization of the real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3: RESEARCH0034, 2002.
21. Catz SD and Johnson JL: Bcl-2 in prostate cancer: a minireview. Apoptosis 8: 29-37, 2003. (Pubitemid 36133135)
22. Lemelynova AA, Grygorenko VM, Cheremuha SV and Romanenko AM: Correlation between histological type and immunohistochemical profile of prostate cancer and Gleason scale gradation. J Exp Oncol 31: 246-249, 2009.
23. Hockenbery DM, Zutter M, Hickey W, Nahm M and Korsmeyer SJ: Bcl2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 88: 6961-6965, 1991. (Pubitemid 21915069)
24. Motz C, Martin H, Krimmer T and Rassow J: Bcl-2 and porin follow different pathways of TOM-dependent insertion into the mitochondrial outer membrane. J Mol Biol 323: 729-738, 2002. (Pubitemid 36160226)
25. Ross K, Rudel T and Kozjak-Pavlovic V: TOM-independent complex formation of Bax and Bak in mammalian mitochondria during TNFalpha-induced apoptosis. Cell Death Differ 16: 697-707, 2009.
26. Schein SJ, Colombini M and Finkelstein A: Reconstitution in planar lipid bilayers of a voltage-dependent anion-selective channel obtained from Paramecium mitochondria. J Membr Biol 30: 99-120, 1976. (Pubitemid 8010351)
27. Benz R: Permeation of hydrophilic solutes through mitochondrial outer membranes: review on mitochondrial porins. Biochim Biophys Acta 1197: 167-196, 1994.
28. Thinnes FP: Evidence for extra-mitochondrial localization of the VDAC/porin channel in eukaryotic cells. J Bioenerg Biomembr 24: 71-75, 1992.
29. De Pinto V, Messina A, Lane DJ and Lawen A: Voltage-dependent anion-selective channel (VDAC) in the plasma membrane. FEBS Lett 584: 1793-1799, 2010.
30. Shoshan-Barmatz V and Mizrachi D: VDAC1: from structure to cancer therapy. Front Oncol 2: 164, 2012.
31. Simamura E, Hirai K, Shimada H, Koyama J, Niwa Y and Shimizu S: Furanonaphthoquinones cause apoptosis of cancer cells by inducing the production of reactive oxygen species by the mitochondrial voltage-dependent anion channel. Cancer Biol Ther 5: 1523-1529, 2006.
32. Hastie C, Saxton M, Akpan A, Cramer R, Master JR and Naaby-Hansen S: Combined affinity labeling and mass spectrometry analysis of differential cell surface protein expression in normal and prostate cancer cells. Oncogene 24: 5905-5913, 2005. (Pubitemid 43080082)
33. Jiang N, Kham SK, Koh GS, Suang Lim JY, Ariffin H, Chew FT and Yeoh AE: Identification of prognostic protein biomarkers in childhood acute lymphoblastic leukemia (ALL). J Proteomics 74: 843-857, 2011.
34. Castagna A, Antonioli P, Astner H, Hamdan M, Righetti SC, Perego P, Zunino F and Righetti PG: A proteomic approach to cisplatin resistance in the cervix squamous cell carcinoma cell line A431. Proteomics 4: 3246-3267, 2004. (Pubitemid 39372405)
35. Nawarak J, Huang-Liu R, Kao SH, Liao HH, Sinchaikul S, Chen ST and Cheng SL: Proteomic analysis of A375 human malignant melanoma cells in response to arbutin treatment. Biochim Biophys Acta 1792: 159-167, 2009.
36. Lai JC, Tan W, Benimetskaya L, Miller P, Colombini M and Stein CA: A pharmacologic target of G3139 in melanoma cells may be the mitochondrial VDAC. Proc Natl Acad Sci USA 103: 7494-7499, 2006.
37. Thinnes FP: Neuroendocrine differentiation of LNcaP cells suggests: VDAC in the cell membrane is involved in the extrinsic apoptotic pathway. Mol Genet Metab 97: 241-243, 2009.
38. Shoshan-Barmatz V, Keinan N and Zaid H: Uncovering the role of VDAC in the regulation of cell life and death. J Bioenerg Biomembr 40: 183-191, 2008.
39. Abu-Hamad S, Sivan S and Shoshan-Barmatz V: The expression level of the voltage-dependent anion channel controls life and death of the cell. Proc Natl Acad Sci USA 103: 5787-5792, 2006.
40. Rostovtseva T and Colombini M: VDAC channels mediate and gate the flow of ATP: implications for the regulation of mitochondrial function. Biophys J 72: 1954-1962, 1997. (Pubitemid 27184425)
41. Tan W, Colombini M: VDAC closure increases calcium ion flux. Biochim Biophys Acta 1768: 2510-2515, 2007. (Pubitemid 47532032)